Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1533935

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1533935

Hemophilia B

PUBLISHED:
PAGES: 188 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Hemophilia B Market to Reach US$6.4 Billion by 2030

The global market for Hemophilia B estimated at US$3.8 Billion in the year 2023, is expected to reach US$6.4 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2023-2030. Moderate Severity Disease, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Mild Severity Disease segment is estimated at 8.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$989.1 Million While China is Forecast to Grow at 7.5% CAGR

The Hemophilia B market in the U.S. is estimated at US$989.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.3% CAGR.

Global Hemophilia B Market - Key Trends and Drivers Summarized

Hemophilia B, also known as Christmas disease, is a rare genetic bleeding disorder caused by a deficiency of factor IX, a protein essential for blood clotting. This condition primarily affects males due to its X-linked recessive inheritance pattern, with females typically being carriers. Hemophilia B can vary in severity, with symptoms ranging from mild to severe bleeding episodes, often triggered by injuries or surgeries. Spontaneous bleeding into joints and muscles is a common complication, leading to pain, swelling, and long-term joint damage if not properly managed. The diagnosis is confirmed through blood tests that measure factor IX activity, and genetic testing can identify carriers and inform family planning decisions. Treatment usually involves regular infusions of recombinant or plasma-derived factor IX concentrates to prevent and control bleeding episodes, greatly improving the quality of life for those affected.

Advancements in medical research have significantly improved the management and understanding of Hemophilia B. Gene therapy has emerged as a promising treatment option, aiming to provide a one-time cure by delivering functional copies of the factor IX gene to the liver, where it can produce the necessary clotting factor. Early clinical trials have shown encouraging results, with patients achieving sustained levels of factor IX activity and a substantial reduction in bleeding episodes. Additionally, extended half-life factor IX products, which require less frequent dosing, have been developed, offering greater convenience and adherence to treatment regimens. These innovations, along with enhanced diagnostic techniques and comprehensive care programs, are transforming the landscape of Hemophilia B management, enabling individuals to lead more active and fulfilling lives.

The growth in the Hemophilia B treatment market is driven by several factors. Technological advancements, such as gene therapy and extended half-life clotting factor products, are providing more effective and convenient treatment options. The increasing prevalence of Hemophilia B, coupled with greater awareness and diagnosis rates, is expanding the patient pool seeking treatment. Improved healthcare infrastructure and access to specialized care in emerging economies are also contributing to market growth. Furthermore, patient advocacy groups and educational initiatives are playing a crucial role in promoting early diagnosis and treatment adherence. The shift towards personalized medicine, where treatments are tailored to individual genetic profiles, is another key driver, enhancing the efficacy and safety of therapies. As pharmaceutical companies invest in research and development, the pipeline of novel therapies continues to grow, promising further advancements in the management of Hemophilia B.

Select Competitors (Total 53 Featured) -

  • Bayer AG
  • Be Biopharma, Inc.
  • Centessa Pharmaceuticals Plc
  • CSL
  • Freeline Therapeutics
  • Grifols USA, LLC
  • Intellia Therapeutics, Inc.
  • LFB Biotechnologies
  • Medexus Pharma, Inc. (IXINITY )
  • novoMEDLINK
  • Pfizer, Inc.
  • Spark Therapeutics, Inc.
  • Swedish Orphan Biovitrum AB (Sobi)
  • Takeda Pharmaceutical Company
  • uniQure N.V.;
Show more
Product Code: MCP27103

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Hemophilia B - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Breakthroughs in Gene Therapy for Hemophilia B Gains Ground
    • Global Spending on Healthcare Infrastructure Improves Accessibility to Factor IX Products
    • Development of Extended Half-life Coagulation Factors Expand Treatment Options
    • Personalized Approaches to the Treatment of Hemophilia B Gains Momentum
    • Aging Population with Hemophilia, a Key Demographic Driver of Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hemophilia B Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hemophilia B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hemophilia B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hemophilia B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Moderate Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Moderate Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Moderate Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Mild Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Mild Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Mild Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Severe Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Severe Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Severe Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for On-Demand Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for On-Demand Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for On-Demand Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Prophylaxis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Prophylaxis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • JAPAN
    • Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • CHINA
    • Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • EUROPE
    • Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Hemophilia B by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Hemophilia B by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Hemophilia B by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • FRANCE
    • Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • GERMANY
    • Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Europe 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hemophilia B Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Asia-Pacific 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Hemophilia B by Disease Severity - Moderate Disease, Mild Disease and Severe Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Hemophilia B by Disease Severity - Percentage Breakdown of Value Sales for Moderate Disease, Mild Disease and Severe Disease for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Hemophilia B by Treatment - On-Demand Therapy, Prophylaxis and Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of World 16-Year Perspective for Hemophilia B by Treatment - Percentage Breakdown of Value Sales for On-Demand Therapy, Prophylaxis and Inhibitors for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!